Study reveals how LL-37 cathelicidin and its citrullinated form differentially modulate IL-17-mediated immune responses, with implications for autoimmune and inflammatory diseases.
Key findingStudy reveals how LL-37 cathelicidin and its citrullinated form differentially modulate IL-17-mediat
What the researchers found
Study reveals how LL-37 cathelicidin and its citrullinated form differentially modulate IL-17-mediated immune responses, with implications for autoimmune and inflammatory diseases.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Study tested LL-37 and citrullinated-LL-37 effects on multiple IL-17A/F-induced inflammatory mediators, with selective Lipocalin-2 suppression identified.
How the study worked
In publication.
Who was studied
In vitro bronchial epithelial cell culture experiments
What this study cannot tell us
In publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide therapeutic knowledge.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
LL-37 and citrullinated-LL-37 modulate IL-17A/F-mediated responses and selectively suppress Lipocalin-2 in bronchial epithelial cells.
Journal of inflammation (London, England), 22(1), 20
Citation
Altieri, Anthony; Lloyd, Dylan; Ramotar, Padmanie; van der Does, Anne M; Hemshekhar, Mahadevappa; Mookherjee, Neeloffer. (2025). LL-37 and citrullinated-LL-37 modulate IL-17A/F-mediated responses and selectively suppress Lipocalin-2 in bronchial epithelial cells.. Journal of inflammation (London, England), 22(1), 20. https://doi.org/10.1186/s12950-025-00446-w